TY - JOUR
T1 - Kinetics of cardiac troponin and other biomarkers in patients with ST elevation myocardial infarction
AU - Kristensen, Jonas Henrik
AU - Koczulab, Clara Amalie Wistisen
AU - Frandsen, Emil Anton
AU - Hasselbalch, Rasmus Bo
AU - Strandkjær, Nina
AU - Jørgensen, Nicoline
AU - Østergaard, Morten
AU - Møller-Sørensen, Peter Hasse
AU - Nilsson, Jens Christian
AU - Afzal, Shoaib
AU - Kamstrup, Pia Rørbæk
AU - Dahl, Morten
AU - Bor, Mustafa Vakur
AU - Frikke-Schmidt, Ruth
AU - Jørgensen, Niklas Rye
AU - Rode, Line
AU - Holmvang, Lene
AU - Kjærgaard, Jesper
AU - Bang, Lia Evi
AU - Forman, Julie
AU - Dalhoff, Kim
AU - Bundgaard, Henning
AU - Iversen, Kasper Karmark
N1 - © 2023 The Authors.
PY - 2023/10
Y1 - 2023/10
N2 - OBJECTIVE: To examine changes in concentration, time-to-peak and the ensuing half-life of cardiac biomarkers in patients with myocardial infarction.METHODS: Blood sampling was performed every third hour within 24 h after percutaneous coronary intervention (PCI) on a cohort of patients with ST elevation myocardial infarction. Cardiac troponin (cTn) was measured by the Dimension Vista, Vitros, Atellica, and Alinity high-sensitivity (hs) cTnI assays, and the Elecsys hs-cTnT assay. Further, creatine kinase (CK), myoglobin, creatine kinase MB (CKMB) and other biomarkers were analyzed.RESULTS: A total of 36 patients completed blood sampling (median age 60 years, IQR 56.4-66.5 years; seven women, 19.4%). Hs-cTnI measured by the Vitros assay was the first hs-cTn to peak at 9.1 h (95%-CI 6.2-10.1) after PCI and 11.7 h (95%-CI 10.4-14.8) after symptoms onset. There were no notable differences between hs-cTn assays in regard to time-to-peak. Also, Vitros hs-cTnI reached the highest median ratio of concentration to upper reference level of nearly 2,000. The median half-life from peak concentration ranged from 7.6 h for myoglobin (CI 6.8-8.6) to 17.8 h for CK (CI 6.8-8.6). For hs-cTn assays the median T½ ranged from 12.4 h for the Vista hs-cTnI assay (95%-CI 11.0-14.1 h) to 17.3 h for the Elecsys hs-cTnT (95%-CI 14.9-20.8 h).CONCLUSIONS: This study updates knowledge on the kinetics of cardiac biomarkers in current clinical use. There was no notable difference in trajectories, time-to-peak or half-life between hs-cTn assays.
AB - OBJECTIVE: To examine changes in concentration, time-to-peak and the ensuing half-life of cardiac biomarkers in patients with myocardial infarction.METHODS: Blood sampling was performed every third hour within 24 h after percutaneous coronary intervention (PCI) on a cohort of patients with ST elevation myocardial infarction. Cardiac troponin (cTn) was measured by the Dimension Vista, Vitros, Atellica, and Alinity high-sensitivity (hs) cTnI assays, and the Elecsys hs-cTnT assay. Further, creatine kinase (CK), myoglobin, creatine kinase MB (CKMB) and other biomarkers were analyzed.RESULTS: A total of 36 patients completed blood sampling (median age 60 years, IQR 56.4-66.5 years; seven women, 19.4%). Hs-cTnI measured by the Vitros assay was the first hs-cTn to peak at 9.1 h (95%-CI 6.2-10.1) after PCI and 11.7 h (95%-CI 10.4-14.8) after symptoms onset. There were no notable differences between hs-cTn assays in regard to time-to-peak. Also, Vitros hs-cTnI reached the highest median ratio of concentration to upper reference level of nearly 2,000. The median half-life from peak concentration ranged from 7.6 h for myoglobin (CI 6.8-8.6) to 17.8 h for CK (CI 6.8-8.6). For hs-cTn assays the median T½ ranged from 12.4 h for the Vista hs-cTnI assay (95%-CI 11.0-14.1 h) to 17.3 h for the Elecsys hs-cTnT (95%-CI 14.9-20.8 h).CONCLUSIONS: This study updates knowledge on the kinetics of cardiac biomarkers in current clinical use. There was no notable difference in trajectories, time-to-peak or half-life between hs-cTn assays.
U2 - 10.1016/j.ijcha.2023.101250
DO - 10.1016/j.ijcha.2023.101250
M3 - Article
C2 - 37602285
SN - 2352-9067
VL - 48
JO - IJC Heart and Vasculature
JF - IJC Heart and Vasculature
M1 - 101250
ER -